<DOC>
	<DOCNO>NCT02401490</DOCNO>
	<brief_summary>To assess whether albumin administration episode hepatic encephalopathy ( ≥ grade II ) improve survival 90 day ( mortality endpoint treat composite endpoint death and/ liver transplantation ) .</brief_summary>
	<brief_title>Albumin Infusion Effects Mortality Patients With Cirrhosis Hepatic Encephalopathy</brief_title>
	<detailed_description>To evaluate whether albumin administration episode hepatic encephalopathy ( ≥ grade II ) improve survival 30 , 90 180 day . - evaluate effect albumin hepatic encephalopathy recurrence study period . - To analyze whether albumin administration reduces hospitalization requirement . - To study effect albumin circulatory dysfunction index ( mean arterial pressure , renal function , plasma vasopressor hormone ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>1 . Age 18 85 year . 2 . Liver cirrhosis define previous clinical data liver biopsy . 3 . Presence episode acute hepatic encephalopathy grade &gt; 2 . 4 . Sign inform consent 1 . Pregnant breastfeeding . 2 . Terminal illness . 3 . Presence Acuteonchronic liver failure . 4 . Needing intensive support measure . 5 . Active gastrointestinal bleeding . 6. neurological psychiatric comorbidity hinders assessment hepatic encephalopathy . 7 . Clinical situation contraindicate administer intravenous albumin . 8 . MELD score less 15 great 25 time inclusion 9 . Any medical condition previous patient inclusion study involve administration albumin previous 7 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>